Literature DB >> 33237305

Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer: Is Rising Utilization Justified by Evidence?

Daniel W Lin1, Peter S Nelson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33237305     DOI： 10.1001/jamaoncol.2020.6045

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  2 in total

1.  Protein signatures to distinguish aggressive from indolent prostate cancer.

Authors:  Fernando Garcia-Marques; Shiqin Liu; Sarah M Totten; Abel Bermudez; Cheylene Tanimoto; En-Chi Hsu; Rosalie Nolley; Amy Hembree; Tanya Stoyanova; James D Brooks; Sharon J Pitteri
Journal:  Prostate       Date:  2022-01-31       Impact factor: 4.104

2.  Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice.

Authors:  Rashid K Sayyid; Laurence Klotz; John Z Benton; Merry Ma; Phillip Woodruff; Raj Satkunasivam; Martha K Terris; Christopher J D Wallis; Zachary Klaassen
Journal:  Can Urol Assoc J       Date:  2021-08-26       Impact factor: 1.862
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.